var data={"title":"Polymethylmethacrylate microspheres soft tissue filler: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Polymethylmethacrylate microspheres soft tissue filler: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/789338?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50470903\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Cosmetic Agent, Implant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50472341\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>A skin test should be performed 4 weeks prior to treatment. Refer to the manufacturer's instructions for use for additional information on the interpretation of skin test results.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nasolabial folds and facial acne scars:</b> Intradermal: &ge;21 years: Inject as needed for cosmetic result; injecting &gt;3.5 mL per treatment site or 8.9 mL overall has not been established. Correction should be limited to no more than 100% of the skin defect during treatment. One or two touch-up implantations at intervals of at least 2 weeks may be required to achieve the desired effect.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50992122\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989358\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50472342\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50472353\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Bring syringe to room temperature before injection. Injection area should be washed with soap and water then cleaned with alcohol or other antiseptic. Refer to manufacturer's instructions for use for comprehensive administration information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50470905\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Nasolabial folds and facial acne scars</b>\n      <b>: </b> Correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients 21 years and older.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46041849\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidences reported with acne scar treatment unless otherwise indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Contact dermatitis (1%), pruritus (nasolabial fold [NLF] and acne scars: &le;1%; NLF: Occurred &gt;48 hours after injection, duration ranged from 3 weeks to &gt;3 months), skin rash (NLF and acne scars: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hyperesthesia (NLF: 2%; duration ranged from 4 weeks to unresolved at 26 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Residual mass at injection site (NLF: 5% [1 month postinjection; duration ranged from 4 weeks to unresolved at 26 weeks], acne scars: &lt;1% [many patients reported residual lumps/bumps up to 2 weeks postinjection]), injection site reaction (4%), tenderness at injection site (acne scars: 4%, NLF: &lt;1% [occasional]), erythema at injection site (NLF: &le;4% [duration ranged from 5 weeks to unresolved at 26 weeks], acne scars: &lt;1% [many patients reported erythema up to 2 weeks postinjection]), swelling at injection site (NLF and acne scars: &le;4%; NLF: duration ranged from 5 weeks to unresolved at 26 weeks), bruising at injection site (2%; many patients reported bruising up to 2 weeks postimplantation), pain at injection site (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (3%), sinusitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abscess, acneiform eruption, acne vulgaris, actinic keratosis, areata alopecia (NLF; some occurrences reported &ge;3 months after injection), atopic dermatitis, bacterial infection, blurred vision, burning sensation, chest congestion (mild), cutaneous papilloma, exacerbation of herpes labialis, flu-like symptoms, granuloma (NLF; duration ranged from 10 weeks to unresolved at 26 weeks), herpes zoster, hordeolum, implant-site complication (NLF; enlargement of implant; duration ranged from 10 weeks to unresolved at 26 weeks), influenza, limb pain, meningitis, otic infection, pharyngitis, puncture wound (NLF; puncture area visible; duration 13 weeks), seborrheic dermatitis, skin discoloration at injection site, squamous cell carcinoma of skin, syncope, telangiectasia (NLF; occasional, some occurrences reported &ge;3 months postinjection), xeroderma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50470909\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to polymethylmethacrylate, lidocaine, bovine collagen, or any component of the formulation; positive response to Bellafill Skin test; patients with severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies; patients undergoing or planning to undergo desensitization injections to meat products; patients with bleeding disorders; patients with susceptibility to keloid formation or hypertrophic scarring; use for lip augmentation and injection into the vermilion or the wet mucosa of the lip.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50471042\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intravascular injection: Inadvertent intravascular injection of dermal fillers may cause embolization, vessel occlusion, ischemia, or infarction resulting in vision impairment or blindness, cerebral hemorrhage or ischemia, skin necrosis, and damage to underlying facial structures. Treatment should be discontinued and patient promptly evaluated if exhibiting any signs or symptoms of intravascular injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin effects: Hyperpigmentation, keloid formation, or hypertrophic scars may occur after dermal filler injections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acne scars: Safety and effectiveness have not been established in patients with non-distensible atrophic acne scars, ice pick scars, or sinus tract scars.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Connective tissue disorder: Safety has not been established in patients with connective tissue disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant/antiplatelet agents: Use within 3 weeks after administration has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppressive therapy: Concomitant use with immunosuppressive therapy has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Other dermal response procedures: Laser treatment, chemical peeling, or similar procedures may elicit an inflammatory response at injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Other wrinkle therapies: Use within 6 months of other wrinkle therapies (eg, collagen, botulinum toxin) has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cold weather: Exposure to extreme cold weather should be minimized until initial swelling and redness have resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Excessive exposure to sun or UV lamp should be minimized until initial swelling and redness have resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin inflammation or infection: Treatment should be deferred if active inflammation (eg, cysts, pimples, rash, hives) or infection present at injection site(s).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin testing: Skin testing must be performed; patients with a positive test, two equivocal tests, or demonstrating an anti-bovine collagen serum IgG level outside the normal range at baseline should not be treated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45525301\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45525298\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=114509&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50470906\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Pregnant women and women of reproductive potential not using effective contraception were excluded from initial studies (Cohen 2004; Joseph 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50470907\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Breastfeeding women were excluded from initial studies (Cohen 2004; Joseph 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50472326\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">After implantation, the bovine collagen component dissipates over the course of 1 to 3 months, leaving behind the nonbiodegradable PMMA microspheres. The microspheres stimulate a local inflammatory reaction that is followed by the deposition of granulation tissue during the first few weeks after implantation. The connective tissue subsequently matures, and by three months after injection, PMMA microspheres are surrounded by newly formed collagen. The presence of new collagen accounts for the observed volume-filling effect (Cohen 2004; Lemperle 2010).</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bellafill (polymethylmethacrylate) [prescribing information]. San Diego, CA: Suneva Medical Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen SR, Holmes RE. Artecoll: a long-lasting injectable wrinkle filler material: Report of a controlled, randomized, multicenter clinical trial of 251 subjects. <i>Plast Reconstr Surg</i>. 2004;114(4):964-976; discussion 977-979.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymethylmethacrylate-microspheres-soft-tissue-filler-drug-information/abstract-text/15468406/pubmed\" target=\"_blank\" id=\"15468406\">15468406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joseph JH, Eaton LL, Cohen SR. Current concepts in the use of Bellafill. <i>Plast Reconstr Surg</i>. 2015;136(5 suppl):171S-179S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymethylmethacrylate-microspheres-soft-tissue-filler-drug-information/abstract-text/26441096/pubmed\" target=\"_blank\" id=\"26441096\">26441096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lemperle G, Knapp TR, Sadick NS, Lemperle SM. ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques. <i>Aesthetic Plast Surg</i>. 2010;34(3):264-272. doi: 10.1007/s00266-009-9413-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymethylmethacrylate-microspheres-soft-tissue-filler-drug-information/abstract-text/19787394/pubmed\" target=\"_blank\" id=\"19787394\">19787394</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 114509 Version 4.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F50470903\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50472341\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50992122\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989358\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F50472342\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50472353\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F50470905\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46041849\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F50470909\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F50471042\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45525301\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45525298\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50470906\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50470907\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F50472326\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/114509|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}